Bamco Inc. NY Purchases New Holdings in Establishment Labs Holdings Inc. $ESTA

Bamco Inc. NY purchased a new position in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 286,098 shares of the company’s stock, valued at approximately $24,550,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. KBC Group NV acquired a new stake in Establishment Labs in the 1st quarter valued at $28,000. Northwestern Mutual Wealth Management Co. acquired a new position in Establishment Labs during the second quarter worth $43,000. Kestra Advisory Services LLC bought a new position in shares of Establishment Labs during the fourth quarter valued at $47,000. Quarry LP bought a new position in shares of Establishment Labs during the third quarter valued at $34,000. Finally, State of Wyoming acquired a new stake in shares of Establishment Labs in the 2nd quarter valued at $87,000. Institutional investors own 72.91% of the company’s stock.

Establishment Labs Stock Up 0.4%

Shares of NASDAQ:ESTA opened at $72.45 on Thursday. The company has a debt-to-equity ratio of 12.11, a current ratio of 3.84 and a quick ratio of 2.52. The stock has a market cap of $2.16 billion, a price-to-earnings ratio of -55.31 and a beta of 1.07. The company has a 50 day moving average of $85.54 and a 200-day moving average of $74.92. Establishment Labs Holdings Inc. has a one year low of $36.53 and a one year high of $97.59.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.05). Establishment Labs had a negative return on equity of 196.69% and a negative net margin of 15.82%.The company had revenue of $67.54 million during the quarter, compared to the consensus estimate of $65.79 million. During the same quarter in the prior year, the business earned ($0.57) earnings per share. The firm’s revenue for the quarter was up 31.7% on a year-over-year basis. On average, sell-side analysts forecast that Establishment Labs Holdings Inc. will post -1.15 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ESTA. JPMorgan Chase & Co. upped their target price on shares of Establishment Labs from $84.00 to $95.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. BTIG Research lifted their price target on shares of Establishment Labs from $96.00 to $103.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Weiss Ratings restated a “sell (e+)” rating on shares of Establishment Labs in a research report on Wednesday, June 24th. Citigroup raised shares of Establishment Labs from a “neutral” rating to a “buy” rating and set a $92.00 price objective on the stock in a research note on Thursday, August 13th. Finally, Needham & Company LLC raised their price objective on shares of Establishment Labs from $86.00 to $95.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Eight analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Establishment Labs presently has an average rating of “Moderate Buy” and a consensus price target of $100.25.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.